Various vaccines are in development, including purified inactivated viral (PIV) particles, purified virus-like particles (VLPs) and viral subunit proteins, live-attenuated vaccines, chimeric vaccines, and viral and nonviral vectors encoding Zika virus structural proteins. Zika purified inactivated virus (ZPIV) vaccine, an investigational vaccine, was found to be well tolerated in a phase I trial. A synthetic DNA vaccine (GLS-500) has shown promise in a phase I trial. A live-attenuated vaccine has also shown promise in animal studies. WHO: progress toward discovery of Zika virus vaccines and therapeutics. external link opens in a new window
While there are currently no specific antiviral treatments available for Zika virus infection, various candidates are being trialed in early-stage trials. Antiviral agents effective against the hepatitis C virus are being tested and have shown activity against Zika virus polymerase. Selected antimalarial drugs have shown activity against Zika virus. A new mouse model may help in exploring the potential activity of Zika virus vaccines and therapeutics.
Use of this content is subject to our disclaimer